Current Report Filing (8-k)
September 18 2019 - 5:23PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
September 16, 2019
Date of report (date of earliest event reported)
MusclePharm Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
000-53166
|
|
77-0664193
|
(State or other jurisdictions of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Nos.)
|
Burbank, CA 91505
(Address of principal executive offices) (Zip Code)
(303) 396-6100
(Registrant’s telephone number, including area
code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrants
under any of the following provisions:
[
]
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
[
]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
[
]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
N/A
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01
Other Events.
Mr.
Ryan Drexler, the Chief Executive Officer, President and Chairman
of the Board of Directors of MusclePharm Corporation, a Nevada
corporation (the “Company”), delivered a notice to the
Company and its independent directors of his election to convert,
effective as of September 16, 2019 (the “Notice Date”),
$18,000,000 of the amount outstanding under that certain Amended
and Restated Convertible Secured Promissory Note, dated as of
November 8, 2017 (the “Note”), issued by the Company to
Mr. Drexler, into shares of the Company’s common stock, par
value $0.001 per share (the “Common Stock”), at a
conversion price of $1.11 per share, pursuant to the terms and
conditions of the Note (the “Partial
Conversion”).
As of
the Notice Date, the total amount outstanding under the Note
(including principal and accrued and unpaid interest) was equal to
$19,262,910.15. Pursuant to the terms of the Note, the Company has
instructed the transfer agent for its shares to issue to Mr.
Drexler 16,216,216 shares (the “Shares”) of its Common
Stock in respect of the Partial Conversion. The Note will remain
outstanding in accordance with its terms in respect of all amounts
in excess of the $18,000,000 that is subject to the Partial
Conversion.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
MUSCLEPHARM CORPORATION
|
|
|
|
|
By:
|
/s/
Alberto Andrade
|
|
|
|
Name:
Alberto Andrade
Title:
Chief Operating Officer
|
Date:
September 18, 2019
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024